127 related articles for article (PubMed ID: 19211500)
1. Sorafenib is active on lung metastases from synovial sarcoma.
Basso U; Brunello A; Bertuzzi A; Santoro A
Ann Oncol; 2009 Feb; 20(2):386-7. PubMed ID: 19211500
[No Abstract] [Full Text] [Related]
2. Objective response to sorafenib in advanced clear-cell sarcoma.
Mir O; Boudou-Rouquette P; Larousserie F; Babinet A; Dumaine V; Anract P; Goldwasser F
Ann Oncol; 2012 Mar; 23(3):807-809. PubMed ID: 22274882
[No Abstract] [Full Text] [Related]
3. Response to trabectedin in a patient with advanced synovial sarcoma with lung metastases.
Zanardi E; Maruzzo M; Montesco MC; Roma A; Rastrelli M; Basso U
Anticancer Drugs; 2014 Nov; 25(10):1227-30. PubMed ID: 25075796
[TBL] [Abstract][Full Text] [Related]
4. Phase II studies in soft tissue sarcoma: time for reappraisal.
Sleijfer S
Oncologist; 2012; 17(2):154-6. PubMed ID: 22285964
[TBL] [Abstract][Full Text] [Related]
5. About sorafenib in castration-resistant prostate cancer.
Colloca G; Checcaglini F; Venturino A
Ann Oncol; 2008 Oct; 19(10):1812-3; author reply 1813-1814. PubMed ID: 18689865
[No Abstract] [Full Text] [Related]
6. The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.
Desar IM; Mulder SF; Stillebroer AB; van Spronsen DJ; van der Graaf WT; Mulders PF; van Herpen CM
Acta Oncol; 2009; 48(6):927-31. PubMed ID: 19452305
[No Abstract] [Full Text] [Related]
7. Feasibility of (125)I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma.
Li C; Zhang F; Zhang W; Zhang L; Huang Z; Wu P
J Cancer Res Clin Oncol; 2010 Nov; 136(11):1633-40. PubMed ID: 20865361
[TBL] [Abstract][Full Text] [Related]
8. Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma.
Chen L; Shen Y; Luo Q; Yu Y; Lu H; Zhu R
Thyroid; 2011 Feb; 21(2):119-24. PubMed ID: 21186953
[TBL] [Abstract][Full Text] [Related]
9. Keratoacanthomas associated with sorafenib therapy.
Kong HH; Cowen EW; Azad NS; Dahut W; Gutierrez M; Turner ML
J Am Acad Dermatol; 2007 Jan; 56(1):171-2. PubMed ID: 17190642
[No Abstract] [Full Text] [Related]
10. Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report.
Li XF; Chen Q; Huang WX; Ye YB
Med Oncol; 2009; 26(2):157-60. PubMed ID: 18846437
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib for HCC: a pragmatic perspective.
Razumilava N; Gores GJ
Oncology (Williston Park); 2011 Mar; 25(3):300, 302. PubMed ID: 21548475
[No Abstract] [Full Text] [Related]
12. Targeting ELF in therapy of liver cancer.
Cancer Biol Ther; 2007 Jul; 6(7):997. PubMed ID: 19358343
[No Abstract] [Full Text] [Related]
13. Sorafenib [corrected] in kidney cancer.
Escudier B
Ann Oncol; 2007 Jul; 18 Suppl 9():ix90-3. PubMed ID: 17631603
[No Abstract] [Full Text] [Related]
14. Metastatic chest wall malignant schwannoma responding to sorafenib: case report and literature review.
Gudena V; Verma N; Post G; Kizziah M; Fenning R; Montero AJ
Cancer Biol Ther; 2008 Jun; 7(6):810-3. PubMed ID: 18376142
[TBL] [Abstract][Full Text] [Related]
15. Incidence of brain metastases in renal cell carcinoma treated with sorafenib.
Massard C; Zonierek J; Gross-Goupil M; Fizazi K; Szczylik C; Escudier B
Ann Oncol; 2010 May; 21(5):1027-31. PubMed ID: 19850637
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib in hepatocellular carcinoma.
Josephs DH; Ross PJ
Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism.
Bellini E; Pia A; Brizzi MP; Tampellini M; Torta M; Terzolo M; Dogliotti L; Berruti A
Ann Oncol; 2011 Apr; 22(4):988-990. PubMed ID: 21321087
[No Abstract] [Full Text] [Related]
18. Hepatocellular carcinoma: sorafenib before liver transplantation?
Braillon A
Hepatology; 2010 Jun; 51(6):2232-3. PubMed ID: 20041410
[No Abstract] [Full Text] [Related]
19. Sorafenib rechalenge in metastatic renal cell carcinoma.
Porta C; Paglino C; Imarisio I
BJU Int; 2012 Sep; 110(6 Pt B):E235. PubMed ID: 22332769
[No Abstract] [Full Text] [Related]
20. Sorafenib in metastatic renal cell carcinoma with sarcomatoid differentiation.
Lekili M; Muezzinoglu T; Nese N; Temeltas G
J Chin Med Assoc; 2010 May; 73(5):262-4. PubMed ID: 20685594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
